We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The CHMP's positive opinion recommends the marketing authorisation of lyophilised Oncaspar as a component of antineoplastic combination therapy in ALL in paediatric patients from birth to 18 years and in adult patients.